Clinical Trial Update: A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the safety and tolerability of a single-dose inhaled levodopa powder (CVT-301) for Parkinson's disease; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CVT-301 (levodopa inhalation powder) (levodopa inhalation powder)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED